Medicare Expands Coverage of Prolaris, Genetic Test for Prostate Cancer Aggressiveness

Medicare Expands Coverage of Prolaris, Genetic Test for Prostate Cancer Aggressiveness
Medicare coverage for Prolaris genetic test, a tool developed by  Myriad Genetics to help predict the aggressiveness of prostate, cancer has been expanded to include patients with favorable intermediate-risk cancer. Men with low- and very low-risk disease are already covered by Medicare for this test, and the recent decision means the Prolaris test will now be available to

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *